Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: The Princess Margaret Hospital experience

British Journal of Urology

Volumn 82, Issue 3, 1998, Pages 366-372

  Michael, M ^a   Tannock, I F ^a   Czaykowski, P M ^a   Moore, M J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adjuvant chemotherapy; Transitional cell carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BLADDER; CANCER SURVIVAL; CLINICAL ARTICLE; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; KIDNEY PELVIS; LYMPH NODE METASTASIS; MALE; NEPHRECTOMY; NEPHROURETERECTOMY; NEUTROPENIA; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; URINARY TRACT; UROGENITAL TRACT TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SALVAGE THERAPY; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0031687782     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00746.x     Document Type: Article

References (19)

1. Sternberg CN. The treatment of advanced bladder cancer. Ann Oncol 1995; 6: 113-26
2. Pagano F. Bassi P. Galetti TP et al. results of contemporary radical cystectomy for invasive bladder cancer. A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and métastases classification. J Urol 1991; 145: 45-50
3. Frazier HA. Robertson E, Dodge RK. Paulson DF. The value of pathologic factors in predicting cancer specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and the prostate. Cancer 1993; 71: 3993-4001
4. Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 1982; 128: 34-6
5. Shinohara M, Okazawa A. Suzuki M. Itakura H, Munakata A. Kinoshita K. Clinical investigation of renal pelvis and ureteral cancer with specific reference to adjuvant chemotherapy. ]pn ] Urol 1995: 86: 1375-82
6. Smith JA, Whitmore WF. Regional lymph node metastasis from bladder cancer. J Urol 1981: 126: 591-3
7. Logothetis CJ, Johnson DE. Chong C et al. Adjuvant cyclophosphamide, doxorubicin, cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988; 6: 1590-6
8. Skinner DG, Daniels JR, Russell ÇA et al The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991: 145:459-67
9. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996: 155: 495-500
10. Stöckle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pNl and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992: 148: 302-7
11. Wei CH, Hseih RK, Chiou TJ. Chen KK, Chang LS. Chen PM. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience. J Urol 1996: 155: 118-21
12. Stöckle M, Meyenburg W. Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995: 153: 47-52
13. Sternberg CN. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Sem Oncol 1996; 23: 621-32
14. Herr HW. Does current chemotherapy improve survival of patients with invasive bladder cancer? Urology 1997; 49: 309-12
15. Harker WG, Meyers F], Freiha FS et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985: 3: 1463-70
16. Sternberg C, Yagoda A, Scher HI et al. Methotrexate, vinblastine. doxorubicin. and cisplatinum for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-58
17. Levine EG, Raghavan D. MVAC for bladder cancer: Time to move forward again. J Clin Oncol 1993; 11: 387-9
18. Saxman SB, Propert KJ, Einhorn LH et al. Long-term followup of a phase III Intergroup study of cisplatin alone or in combination with methotrexate, vinblastine. and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9
19. Tannock I, Gospodarowicz M, Connolly J, Jewett M. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 1989; 142: 289-92